{"type":"trials","record":{"id":41566,"source_id":"clinicaltrials-gov","external_id":"NCT05637255","title":"A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)","brief_summary":"The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Sylentis, S.A.","enrollment":99,"countries":["Czechia","Poland","Slovakia"],"start_date":"2022-11-22","completion_date":"2024-12-19","last_update_date":"2026-04-13","source_url":"https://clinicaltrials.gov/study/NCT05637255","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":null,"organization":"Sylentis, S.A.","interventions":["SYL1801"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from Baseline on visual acuity on Day 42 after last instillation of the assigned dose level — 42 days after firs…","Proportion of subjects within each cohort who maintained visual acuity on Day 42 after last instillation of the assigne…","Proportion of subjects within each cohort who gained visual acuity on Day 42 after last instillation of the assigned do…","Proportion of subjects within each cohort who needed rescue medication at any point of the study — Through study comple…","Change from Baseline on flow area on Day 42 after last instillation of the assigned — 42 days after first administration","Change from Screening on leakage area on Day 42 after last instillation of the assigned — 43 days after first administr…","Change from Baseline on intraocular pressure (IOP) — 42 days after first administration","Adverse Event Evaluation — Through study completion, up to 42 days"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Macular Degeneration","Neovascular Age-related Macular Degeneration","Macular Degeneration","SYL1801"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05637255","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-11-22 to 2024-12-19","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.834Z","intervention":["SYL1801"],"participants":99,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from Baseline on visual acuity on Day 42 after last instillation of the assigned dose level — 42 days after firs…","Proportion of subjects within each cohort who maintained visual acuity on Day 42 after last instillation of the assigne…","Proportion of subjects within each cohort who gained visual acuity on Day 42 after last instillation of the assigned do…","Proportion of subjects within each cohort who needed rescue medication at any point of the study — Through study comple…","Change from Baseline on flow area on Day 42 after last instillation of the assigned — 42 days after first administration","Change from Screening on leakage area on Day 42 after last instillation of the assigned — 43 days after first administr…","Change from Baseline on intraocular pressure (IOP) — 42 days after first administration","Adverse Event Evaluation — Through study completion, up to 42 days"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41566","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}